270 related articles for article (PubMed ID: 12586669)
1. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
[No Abstract] [Full Text] [Related]
2. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
Pollard AJ; Green C; Sadarangani M; Snape MD
Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
[No Abstract] [Full Text] [Related]
3. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
4. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
[TBL] [Abstract][Full Text] [Related]
6. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
Maiden MC; Ibarz-Pavón AB; Urwin R; Gray SJ; Andrews NJ; Clarke SC; Walker AM; Evans MR; Kroll JS; Neal KR; Ala'aldeen DA; Crook DW; Cann K; Harrison S; Cunningham R; Baxter D; Kaczmarski E; Maclennan J; Cameron JC; Stuart JM
J Infect Dis; 2008 Mar; 197(5):737-43. PubMed ID: 18271745
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
8. New frontiers in meningococcal vaccines.
Anderson AS; Jansen KU; Eiden J
Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
[TBL] [Abstract][Full Text] [Related]
9. Serogroup A meningococcal conjugate vaccines in Africa.
Kristiansen PA; Jørgensen HJ; Caugant DA
Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
[TBL] [Abstract][Full Text] [Related]
11. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
Trotter CL; Edmunds WJ; Ramsay ME; Miller E
Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
[TBL] [Abstract][Full Text] [Related]
12. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
Bröker M
Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
[TBL] [Abstract][Full Text] [Related]
13. Estimating the burden of serogroup C meningococcal disease in England and Wales.
Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
15. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
16. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.
Campbell H; Andrews N; Borrow R; Trotter C; Miller E
Clin Vaccine Immunol; 2010 May; 17(5):840-7. PubMed ID: 20219881
[TBL] [Abstract][Full Text] [Related]
17. Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998.
Davison KL; Crowcroft NS; Ramsay ME; Begg NT; Kaczmarski EB; Stuart JM; White JM; Orr H;
Commun Dis Public Health; 2002 Sep; 5(3):205-12. PubMed ID: 12434690
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
[TBL] [Abstract][Full Text] [Related]
19. Impact of meningococcal C conjugate vaccine use in Australia.
Booy R; Jelfs J; El Bashir H; Nissen MD
Med J Aust; 2007 Feb; 186(3):108-9. PubMed ID: 17309394
[No Abstract] [Full Text] [Related]
20. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
